Latest News
In this issue:
- President’s Corner
- Researcher Spotlight: Shannon Macauley, PhD
- Rare APOE Variant Reduces Plaques Linked to Alzheimer’s
- And more!
In this issue:
- Glaucoma and Corneal Thickness
- President’s Corner
- Identifying New Risk Factors and Treatments for Glaucoma
- And more!
BrightFocus Foundation’s 2022 annual report highlights an incredible year of pioneering neurodegenerative research.
A recent article coauthored by BrightFocus Vice President, Scientific Affairs Diane Bovenkamp, PhD, proposes a new way to narrow racial and ethnic disparities in Alzheimer’s research through the development of standardized electronic health records.
BrightFocus Foundation yesterday presented its first-ever Alzheimer’s Disease Research (ADR) named awards to two leading researchers in recognition of their innovative work to prevent, treat, and, ultimately, cure Alzheimer’s disease.
The newly expanded accessible audio program will connect patients with vision experts and provide the latest glaucoma research news.
Jason Meyer, PhD, is a BrightFocus Foundation success story and a pioneer in the effort to regenerate eye tissue that is damaged by glaucoma.
Findings are the first to show a statistically significant decrease in cognitive decline by an anti-amyloid drug.
New BrightFocus-funded research explores how a protein called tau, critical to Alzheimer’s, turns from normal to a diseased state. This discovery presents a new target to potentially prevent or treat Alzheimer's disease.
Eye-brain research is revealing that the APOE4 mutation has a much different impact in glaucoma than in Alzheimer’s, a discovery that may lead to a new glaucoma treatment.
